ESMO 2017: Combination Therapy With Radium-223 in Metastatic Renal Cell Carcinoma With Bone Metastases
In patients with metastatic renal cell carcinoma who have bone metastases, radium-223 combined with pazopanib or sorafenib appeared to be safe and well tolerated treatment, resulting in a significant decline in all five bone turnover markers. The initial data from a phase I trial were presented by Dominick Bossé, MD, of Dana-Farber Cancer Institute, at the 2017 European Society for Medical Oncology (ESMO) Congress (Abstract 854PD).
In the trial, 30 patients received treatment, and 70% had clear cell histology. Those who were treatment-naive received pazopanib and radium-223 (n=15), and those who were treatment-refractory received sorafenib plus radium-223 (n=15). Radium-223 was administered monthly for up to six infusions.
All bone turnover markers declined significantly. The median treatment duration was 3.6 months, and progression-free survival was 8.2 months and 4.6 months in patients treated with pazopanib and sorafenib, respectively. Prior symptomatic skeletal events were reported in 100% and 65% of patients in the pazopanib and sorafenib cohorts. During the study, the overall rate of symptomatic skeletal events was 47%, including 67% in the pazopanib cohort and 27% in the sorafenib cohort.